FMC CORP reported second-quarter 2026 results with revenue of $867.1M, down from $1.05B a year earlier, and a net loss attributable to stockholders of $186.6M, or diluted loss per share of ($1.49), versus net income of $66.7M and EPS of $0.53 in the prior-year quarter.
Financial Highlights
| MetricCurrent quarterPrior year quarterYoY change | Revenue¹$867.1M$1.05B(17.5%) | Net income²($186.6M)$66.7M(379.8%) | Diluted EPS³($1.49)$0.53(381.1%) |
¹ Reported as “Revenue”. ² Reported as “Net income (loss) attributable to FMC stockholders”. ³ Reported as “Diluted earnings (loss) per common share attributable to FMC stockholders”.
Business Highlights
- Revenue decline driven by lower volumes and pricing pressure across core legacy products; organic revenue fell roughly 22%.
- Volume declines were notable in North America (about 22%) and Asia (about 20%); Latin America and EMEA also down. The India commercial business is held for sale.
- Company continues investing in new active ingredients including Isoflex®, fluindapyr, Dodhylex™ and rimisoxafen while managing post-patent transition for Rynaxypyr®.
- Operational actions include launching Project Foundation restructuring (expected savings and plant exits), signing a rimisoxafen supply/license deal, and a framework real estate sale to free assets.
Original SEC Filing:
This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.